Pexastimogene devacirepvec is under clinical development by Sillajen Biotherapeutics and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Metastatic Renal Cell Carcinoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pexastimogene devacirepvec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pexastimogene devacirepvec overview
Pexastimogene devacirepvec (JX-594) is under development for the treatment of metastatic melanoma, muscle-invasive bladder cancer (MIBC), soft tissue sarcoma, breast cancer, solid tumor, stomach cancer, cholangiocarcinoma, prostate cancere, renal cell carcinoma and metastatic colorectal cancer. The drug candidate is administered through intratumoral and intravenous routes. JX-594 is a Wyeth strain vaccinia virus with a disruption of the viral thymidine kinase (tk) gene and expression of the immunostimulatory cytokine, GM-CSF (granulocyte macrophage colony-stimulating factor). The drug candidate is developed based on SOLVE (Selective Oncolytic Vaccinia Engineering) platform.
It was also under development for the treatment of hepatocellular carcinoma, non-small cell lung cancer, head and neck cancer squamous cell carcinoma, colorectal cancer, kidney cancer, pancreatic cancer, and ovarian cancer.
Sillajen Biotherapeutics overview
Sillajen Biotherapeutics (SillaJen) is a biotechnology company. It designs and develops oncolytic immunotherapeutics for the treatment of cancer. The company’s pipeline products comprise Pexa-Vec, an oncolytic immunotherapeutic virus which is in Phase III trial that is used for the treatment of primary liver cancer. It also develops JX929, a chemosensitizing oncolytic immunotherapy that eradicates cancer; activates chemotherapy in cancer tissue; administers as a monotherapy to patients with breast, colorectal, and pancreatic cancer; and treats melanoma and metastatic colon cancer. The company operates in South Korea and the US. Sillajen is headquartered in San Francisco, the US.
For a complete picture of Pexastimogene devacirepvec’s drug-specific PTSR and LoA scores, buy the report here.